Table 2

Effect of celecoxib and LGD1069 on tumor latency and multiplicity in MMTV/neu mice

Drug regimenMedian time to tumor formation, dPTumor multiplicity (mean ± SD)P
Vehicle304 (n = 32)1.31 ± 1.00 (n = 32)
Celecoxib (500 ppm)285 (n = 29)0.26*2.03 ± 1.38 (n = 29)0.13
LGD1069 (10 mg/kg)420 (n = 26)0.0085*1.27 ± 0.87 (n = 26)1.0
Celecoxib and LGD1069>600 (n = 26)<0.0001,* 0.01250.58 ± 0.78 (n = 24)0.041, 0.068§
  • *P value obtained by comparison with vehicle-treated cohort (log-rank test).

  • P value obtained by comparison with LGD1069-treated cohort (log-rank test).

  • P value obtained by comparison with vehicle-treated cohort (Poisson regression, corrected for multiple comparisons by Tukey's method).

  • §P value obtained by comparison with LGD1069-treated cohort (Poisson regression, corrected for multiple comparisons by Tukey's method).